Gland Pharma Limited — Updates, 12-08-2025: Press Release

Gland Pharma has secured USFDA approval for Cangrelor for Injection 50mg/vial, a key generic injectable. This product is bioequivalent to KENGREAL, used to reduce risks during coronary interventions. Crucially, Gland Pharma gains 180 days of generic drug exclusivity, providing a competitive edge upon launch. The market for this product in the US was significant, with sales around USD 122 million in the last year. This approval marks a positive operational development, potentially boosting Gland's US revenue streams.